The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity
Abstract
PURPOSE: We compare the therapeutic efficacy and toxicity of intravesical bacillus Calmette-Guerin (BCG) with mitomycin C on recurrence of stages Ta and T1 bladder carcinoma. MATERIALS AND METHODS: Combined published and unpublished data from comparative studies on BCG versus mitomycin C for superficial bladder carcinoma considering possible confounding factors were analyzed. Odds ratio (OR) and its 95% CI were used as primary effect size estimate. Toxicity data were evaluated descriptively. RESULTS: In 11 eligible clinical trials 1,421 patients were treated with BCG and 1,328 were treated with mitomycin C. Within the overall median followup time of 26 months 38.6% of the patients in the BCG group and 46.4% of those in the mitomycin C group had tumor recurrence. In 7 of 11 studies BCG was significantly superior to mitomycin C, in 3 studies no significant difference was found, while in 1 study mitomycin C was significantly superior to BCG. An overall statistically significant superiority of BCG versus mitomycin C efficacy in reducing tumor recurrence was detected (OR 0.56, 95% CI 0.38 to 0.84, p = 0.005). In the subgroup treated with BCG maintenance all 6 individual studies showed a significant superiority of BCG over mitomycin C (OR 0.43, 95% CI 0.35 to 0.53, p <0.001). In 4 of the 5 studies with reported data on toxicity BCG associated cystitis was significantly more frequent than in the mitomycin C group (53.8% versus 39.2%). The combined cystitis OR was 1.81 (95% CI 1.48 to 2.23, p <0.001). The OR for cystitis in the BCG maintenance group did not significantly differ from that in the nonmaintenance therapy group. CONCLUSIONS: The results suggest superiority of BCG over mitomycin C for prevention of tumor recurrences in the combined data and particularly in the BCG maintenance treatment subgroup, irrespective of the actual (intermediate or high) tumor risk status. The toxicity with BCG is higher but does not differ between BCG maintenance and nonmaintenance groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Sullivan, J., Sarosdy, M. F., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251703 · Cited by 605
Oosterlinck, W., Lobel, B., Jakse, G., Malmström, P.-U., Stöckle, M., & Sternberg, C. (2002) · European Urology · doi:10.1016/s0302-2838(01)00026-4 · Cited by 464
Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B., Sylvester, R., & Embers of the European Organization for Research and Treatment of Cancer Genitourinary Group (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36198-0 · Cited by 361
Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., & Mason, M. D. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02306.x · Cited by 313
Pawinski, A., Sylvester, R., Kurth, K. H., Bouffioux, C., Van Der Meijden, A., Parmar, M. K. B., Bijnens, L., For the Members of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group, & The Medical Research Council Working Party on Superficial Bladder Cancer (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65396-5 · Cited by 301
Smith, J. A. J., Labasky, R. F., Cockett, A. T. �., Fracchia, J. A., Montie, J. E., & Rowland, R. G. (1999) · PubMed · Cited by 215
SMITH, J. A., LABASKY, R. F., COCKETT, A. T. K., FRACCHIA, J. A., MONTIE, J. E., & ROWLAND, R. G. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68208-0 · Cited by 197
Krege, S., Giani, G., Meyer, R., Otto, T., & Rubben, H. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65673-8 · Cited by 195
Debruyne, F. M. J., Pm, V. D. M., Witjes, J. A., et al. (1992) · Urology · Cited by 14
Cited by
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Self-citationThomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 367
Agrawal, M. S., Agrawal, M., Bansal, S., Agarwal, M., Lavania, P., & Goyal, J. (2007) · Urology · doi:10.1016/j.urology.2007.07.017 · Cited by 44
Metadata
- Authors
- BÖHLE, A., JOCHAM, D., & BOCK, P. R.
- Venue
- Journal of Urology
- Published
- 2003-01
- Volume
- 169
- Issue
- 1
- Pages
- 90-95
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2152445257
- Cited by
- 616
- References
- 11
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity. https://app.cochat.ai/papers/10.1016/s0022-5347(05)64043-8
- The paper
- BÖHLE, A., JOCHAM, D., & BOCK, P. R. (2003). Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)64043-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
